Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Return to Insights Center

Related Insights

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Blog

Optimize your CMC strategy: Five steps to avoid regulatory setbacks

May 15, 2025

Whitepaper

How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU

Jun 28, 2023

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Playbook

Are you using real-world evidence?

Feb 1, 2023

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Webinar

How to navigate China’s regulatory environment

Feb 15, 2023

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Related Insights

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Blog

Optimize your CMC strategy: Five steps to avoid regulatory setbacks

May 15, 2025

Whitepaper

How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU

Jun 28, 2023

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Playbook

Are you using real-world evidence?

Feb 1, 2023

Show more